COMMUNIQUÉS West-GlobeNewswire

Verano Continues Expansion of Florida Operations with the Opening of MÜV Deltona, Elevating the Company’s Retail Footprint to 83 Florida Locations and 160 Dispensaries Nationwide
27/01/2026
MÜV Deltona is located at 1670 Providence Boulevard, a busy thoroughfare with an average daily traffic count of 8,600 vehicles 1 The new Deltona dispensary complements four existing MÜV locations in Volusia County, a [...]
Greenwich LifeSciences Provides Update on FLAMINGO-01 Cash Burn Rate and Financing Strategy
27/01/2026
STAFFORD, Texas, Jan. 27, 2026 (GLOBE NEWSWIRE) -- Greenwich LifeSciences, Inc. (Nasdaq: GLSI) (the "Company"), a clinical-stage biopharmaceutical company focused on its Phase III clinical trial, FLAMINGO-01, which is [...]
Evestia Clinical Acquires ICRC-Weyer to Enhance Global Full-Service Clinical Research Capabilities
27/01/2026
Acquisition adds further specialist biostatistics, data management, and medical writing expertise to Evestia Clinical’s full-service offering and strengthens its presence in Germany and across Europe LONDON, Jan. 27, [...]
Zymeworks Announces Participation in Upcoming Investor Conferences
27/01/2026
VANCOUVER, British Columbia, Jan. 27, 2026 (GLOBE NEWSWIRE) -- Zymeworks Inc . (Nasdaq: ZYME), a biotechnology company managing a portfolio of licensed healthcare assets, while developing a diverse pipeline of novel, [...]
Cardiff Oncology Announces Positive Update from its Randomized Phase 2 Trial of Onvansertib in First-line RAS-mutated mCRC
27/01/2026
- Onvansertib added to FOLFIRI/bev first-line standard of care regimen showed dose-dependent improvement in overall response rates and durability trends as measured by progression-free survival in patients with RAS- [...]
Opus Genetics Launches Gene Therapy Clinical Trial for MERTK-related Retinitis Pigmentosa
27/01/2026
The trial is funded through Abu Dhabi’s Healthcare Research and Innovation Fund Clinical development activities will commence at Cleveland Clinic Abu Dhabi in 2026 MERTK-related retinitis pigmentosa affects an estimated [...]
Cardiff Oncology Announces Executive Leadership Changes as it Transitions to Late-Stage Clinical Development
27/01/2026
SAN DIEGO, Jan. 27, 2026 (GLOBE NEWSWIRE) -- Cardiff Oncology, Inc. (Nasdaq: CRDF), a clinical-stage biotechnology company leveraging PLK1 inhibition to develop novel therapies across a range of cancers, today announced [...]
Axsome Therapeutics to Report Fourth Quarter and Full Year 2025 Financial Results on February 23
27/01/2026
NEW YORK, Jan. 27, 2026 (GLOBE NEWSWIRE) -- Axsome Therapeutics, Inc. (NASDAQ: AXSM), a biopharmaceutical company leading a new era in the treatment of central nervous system (CNS) disorders, today announced it will [...]
Transpire Bio’s ANDA for Generic Trelegy® Ellipta® Accepted for Filing by the U.S. FDA
27/01/2026
SUNRISE, Fla., Jan. 27, 2026 (GLOBE NEWSWIRE) -- Transpire Bio, an integrated clinical-stage biopharmaceutical company focused on developing inhaled therapeutics for pulmonary and systemic diseases, today announces that [...]
StarkAge Therapeutics Announces Research Collaboration with Gustave Roussy to Advance Senolytic Therapies in Digestive Cancers
27/01/2026
PRESS RELEASE StarkAge Therapeutics Announces Research Collaboration with Gustave Roussy to Advance Senolytic Therapies in Digestive Cancers The collaboration will inform patient selection for treatment with STX-1, a [...]
Sevaro Health Expands Leadership Team with Key Appointments
27/01/2026
NEW YORK, Jan. 27, 2026 (GLOBE NEWSWIRE) -- Sevaro Health , the company transforming neurological and specialty care through advanced technology, today announced the appointments of Carl Dugart as Chief Technology [...]
Aclaris Therapeutics’ Novel ITK/JAK3 Inhibitor ATI-2138 Demonstrates Rapid and Sustained Hair Regrowth in Validated Murine Model of Alopecia Areata (AA)
27/01/2026
- ATI-2138 Outperforms Ritlecitinib in Reversal Model of Alopecia Universalis, the Most Severe AA Phenotype - WAYNE, Pa., Jan. 27, 2026 (GLOBE NEWSWIRE) -- Aclaris Therapeutics, Inc. (NASDAQ: ACRS), a clinical-stage [...]
Biotech Veteran and Virologist Joins CancerVax as Senior Scientific Advisor
27/01/2026
Dr. George Kemble, former AstraZeneca executive, to advise the Company on immunological and viral strategies for its novel cancer treatment platform Lehi, Utah, Jan. 27, 2026 (GLOBE NEWSWIRE) -- Lehi, Utah, January 27, [...]
Boehringer Ingelheim and Simcere partner to advance a dual-target antibody treatment to address unmet needs in inflammatory bowel disease
27/01/2026
Novel TL1A/IL23p19 b ispecific antibody targets driv ers of disease pathogenesis to overcome the efficacy ceiling in inflammatory bowel disease . License and collaboration agreement strengthen Boehringer’s inflammatory [...]
Distractions Down, Confidence Up: New AI Colonoscopy Software Delivers More Transparent Polyp Detection
27/01/2026
OSLO, Norway, Jan. 27, 2026 (GLOBE NEWSWIRE) -- Augere Medical (“Augere”), a European pioneer in AI-assisted colonoscopy, today announced the commercial release of its next-generation software module 1.9 for real-time [...]
EPIDAREX CAPITAL ANNOUNCES FIRST CLOSE OF FUND IV, SECURING $145 MILLION TO BUILD NEXT WAVE OF LIFE SCIENCE START-UPS
27/01/2026
EPIDAREX CAPITAL ANNOUNCES FIRST CLOSE OF FUND IV, SECURING $145 MILLION TO BUILD NEXT WAVE OF LIFE SCIENCE START-UPS New Fund will target company creation and early-stage investing across the UK and the US Fund backed [...]
Genenta Announces Strategic Transformation into a Biotech, Defense, Aerospace, and National Security Industrial Consolidator
27/01/2026
Building on Biotech Heritage, Expanding into Defense and National Security Through Industrial Integrations of Privately Held Specialized Italian Companies ATC - a Defense-Sector Company: First Industrial Integration [...]
Fangzhou Issues Positive Profit Forecast as AI-Driven Chronic Care Model Delivers First Full-Year Profit
27/01/2026
SHANGHAI, Jan. 27, 2026 (GLOBE NEWSWIRE) -- Fangzhou Inc. (“Fangzhou” or the “Company”) (HKEX: 06086), a leading provider of AI-driven Internet healthcare solutions, issued a positive profit forecast for 2025, citing [...]
[Ad hoc announcement pursuant to Art. 53 LR] Roche announces positive Phase II results for its dual GLP-1/GIP receptor agonist CT-388 in people living with obesity
27/01/2026
A once-weekly subcutaneous injection of CT-388 achieved a statistically significant placebo-adjusted weight loss of 22.5% (p < 0.001) at 48 weeks at the highest dose tested (24 mg), without reaching a weight loss [...]

Pages